DNA methylation-mediated ADA overexpression drives pancreatic cancer progression.

ABSTRACT:

Background

Pancreatic cancer (PC) is characterized by its aggressive nature, limited options for radiochemotherapy, and poor prognosis, highlighting the urgent need for the identification of novel therapeutic targets to broaden treatment strategies.

Methods

We employed a two-sample Mendelian randomization (MR) approach, utilizing genetically informed druggable genes to identify key genes associated with PC risk. To validate these candidate targets, we conducted sensitivity, colocaliztion, and summary data-based MR (SMR) analyses. Furthermore, DNA methylation mediation analysis was utilized to investigate upstream regulatory mechanisms of significant genes.

Results

At a false discovery rate (FDR) of less than 0.05, five druggable genes were found to be significantly as

SUBMITTER: Zeng J 

PROVIDER: S-EPMC12712253 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature